• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

    18.59 +1.99 (+11.99%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,814,805
    Open 16.41
    Bid (Size) 17.96 (100)
    Ask (Size) 18.85 (200)
    Prev. Close 16.60
    Today's Range 16.21 - 18.70
    52wk Range 14.43 - 50.40
    Shares Outstanding 58,102,949
    Dividend Yield 77.57%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
    From Pomerantz LLP
    Via GlobeNewswire

    Performance

    YTD
    +16.2%
    +16.2%
    1 Month
    +8.8%
    +8.8%
    3 Month
    -52.1%
    -52.1%
    6 Month
    -43.2%
    -43.2%
    1 Year
    -19.9%
    -19.9%

    More News

    Read More
    News headline image
    LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 5, 2025 ↗
    Via Benzinga
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics to Present at Upcoming Investor Conferences
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    10 Health Care Stocks Whale Activity In Today's Session ↗
    Via Benzinga
    News headline image
    LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q3 2025 Revenue Beat and Progress on VIZZ Launch ↗
    Via Chartmill
    News headline image
    LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation
    Via MarketMinute
    Topics Artificial Intelligence
    News headline image
    LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People ↗
    Via Benzinga
    News headline image
    LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lenz (LENZ) Q2 Revenue Jumps 604% ↗
    Via The Motley Fool
    News headline image
    LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics to Present at Upcoming Investor Conferences
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is LENZ Therapeutics, Inc. - Common Stock publicly traded?
    Yes, LENZ Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does LENZ Therapeutics, Inc. - Common Stock trade on?
    LENZ Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for LENZ Therapeutics, Inc. - Common Stock?
    The ticker symbol for LENZ Therapeutics, Inc. - Common Stock is LENZ on the Nasdaq Stock Market
    What is the current price of LENZ Therapeutics, Inc. - Common Stock?
    The current price of LENZ Therapeutics, Inc. - Common Stock is 18.59
    When was LENZ Therapeutics, Inc. - Common Stock last traded?
    The last trade of LENZ Therapeutics, Inc. - Common Stock was at 01/14/26 04:00 PM ET
    What is the market capitalization of LENZ Therapeutics, Inc. - Common Stock?
    The market capitalization of LENZ Therapeutics, Inc. - Common Stock is 1.08B
    How many shares of LENZ Therapeutics, Inc. - Common Stock are outstanding?
    LENZ Therapeutics, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.